SUPN - Supernus Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue215,003147,46592,678
Cost of Revenue11,9868,4235,758
Gross Profit203,017139,04286,920
Operating Expenses
Research Development42,79129,13519,586
Selling General and Administrative106,01089,06372,612
Non Recurring---
Total Operating Expenses---
Operating Income or Loss54,21620,844-5,278
Income from Continuing Operations
Total Other Income/Expenses Net1,244-1,464604
Earnings Before Interest and Taxes55,46019,380-4,674
Interest Expense5,0914,7705,621
Income Before Tax50,36914,610-10,295
Income Tax Expense-40,852666630
Minority Interest---
Net Income From Continuing Ops90,55011,606-13,517
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income91,22113,944-10,925
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares91,22113,944-10,925